Dr Catherine Tang

  • BSc(Med)Hons, MBBS(Hons I), FRACP, FRCPA
  • Haematologist
  • Spoken languages English, Cantonese, Mandarin

Overview

I am a dedicated advocate for my patients, endeavouring to combine the best evidence-based care with perspective, understanding and kindness.

Awards received

  • American Society of Haematology Clinical Training Research Institute Grant
  • Canadian Lymphoproliferative Disorders Young Investigator Award
  • European Haematology Association Young Investigator Travel Grant
  • University of Sydney School of Public Health Clinical Epidemiology Scholarship

Research interests

  • Lymphoma clinical trials
  • Immunotherapy
  • Cellular therapies

Publications and affiliations

  • Tang, C., Espin-Garcia, O, Prica, A., Kukreti, V., Kridel, R., Keating, A., Patriquin, C., Kuruvilla, J & Crump, M. Efficacy and safety of stem cell mobilization following gemcitabine, dexamethasone, cisplatin (GDP) salvage chemotherapy in patients with relapsed or refractory lymphoma. Leukemia & Lymphoma. 2020 61(9):2153-2160
  • Tang, C., Rabbolini, DJ., Morel-Kopp, MC., Connor DE., Cripsin, P., Ward CM & Stevenson, WS. Clinical heterogeneity of RUNX1 associated familial platelet disorder with predisposition to myeloid malignancy. Research and Practice in Thrombosis and Haemostasis 2020 4(1):106-110
  • Tang, C. & Kuruvilla, J. Optimal management of mantle cell lymphoma in the primary setting. Expert Reviews in Hematology. 2019. 12(9):715-721

Professional memberships

  • Australasian Lymphoma and Leukaemia Research Group (ALLG) –  Supportive Care and Lymphoma Working Party member.
  • Haematology Society of Australia & New Zealand (HSANZ) member
  • American Society of Haematology (ASH) member
  • Australasian Lymphoma Alliance (ALA) member
  • NSW eVIQ Haematology and BMT reference committee member